Gilead Sciences
GILD
155.55
+2.48
+1.62%
Gilead Sciences
US · GILD
#110 by market cap
Listed 1992
155.55
+2.48
+1.62%
Live - 5344 symbols - heartbeat 0s ago
· 2026-10-20 11:00
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 91.29% -0.07pp
- Institutions
- 2,709 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund77.66%
Public Company4.16%
Government Pension Fund2.47%
Hedge Fund2.14%
Private Company2.03%
Sovereign Wealth Fund1.86%
Insurance Company0.32%
Corporate Pension Plan0.21%
Family Office/Trust0.18%
Other8.96%
Top holders as of 2026-06-30
BlackRock
9.83% · 121.84M sh
Vanguard Capital Management, LLC
7.10% · 88.06M sh
State Street Global Advisors
4.94% · 61.22M sh
Capital Research
4.90% · 60.79M sh
FMR
4.75% · 58.95M sh
Other
68.48%
Invesco Capital Management LLC
3.01% · 37.34M sh
Vanguard Portfolio Management, LLC
2.85% · 35.32M sh
T. Rowe Price Group, Inc.
2.44% · 30.27M sh
Geode Capital Management, LLC
2.42% · 30.07M sh
Dodge & Cox
1.91% · 23.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Patrick O'Day | Chairperson & CEO | 0.05% |
| Andrew Dickinson | Chief Financial Officer | 0.01% |
| Johanna Mercier | Chief Commercial Officer | 0.01% |
| Diane Wilfong | Former Senior VP, Corporate Controller & Chief Accounting Officer | 0.00% |
| Deborah Telman | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 0.00% |
| Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer | 0.00% |
| Jacqueline Barton | Independent Director | 0.00% |
| Dietmar Berger | Chief Medical Officer | 0.00% |
| Harish Manwani | Independent Director | 0.00% |
| Javier Rodriguez | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-14 | Andrew Dickinson | Chief Financial Officer | Intent to Sell (Form 144) | -3,000 | $156.22 |
| 2026-10-14 | Johanna Mercier | Chief Commercial & Corporate Affairs Officer | Intent to Sell (Form 144) | -3,000 | $156.22 |
| 2026-09-30 | Daniel Patrick O'Day | Chairperson & CEO | Automatic Disposition | -15,000 | $147.72–148.63 |
| 2026-09-21 | Erin Burkhart | Chief Accounting Officer | Derivative Exercise and Sale | -768 | $152.67 |
| 2026-09-21 | Erin Burkhart | Chief Accounting Officer | Derivative Exercise and Retained | +1,455 | -- |
| 2026-09-14 | Andrew Dickinson | Chief Financial Officer | Automatic Disposition | -3,000 | $145.29 |
| 2026-09-14 | Johanna Mercier | Chief Commercial & Corporate Affairs Officer | Automatic Disposition | -3,000 | $143.69–145.29 |
| 2026-09-09 | Andrew Dickinson | Chief Financial Officer | Derivative Exercise and Sale | -1,347 | $144.81 |
| 2026-09-09 | Andrew Dickinson | Chief Financial Officer | Derivative Exercise and Retained | +1,450 | -- |
| 2026-09-09 | Daniel Patrick O'Day | Chairperson & CEO | Derivative Exercise and Sale | -4,230 | $144.81 |
| 2026-09-09 | Daniel Patrick O'Day | Chairperson & CEO | Derivative Exercise and Retained | +4,550 | -- |
| 2026-09-09 | Johanna Mercier | Chief Commercial & Corporate Affairs Officer | Derivative Exercise and Sale | -1,347 | $144.81 |
| 2026-09-09 | Johanna Mercier | Chief Commercial & Corporate Affairs Officer | Derivative Exercise and Retained | +1,450 | -- |
| 2026-09-09 | Dietmar Berger | Chief Medical Officer | Derivative Exercise and Sale | -263 | $144.81 |
| 2026-09-09 | Dietmar Berger | Chief Medical Officer | Derivative Exercise and Retained | +270 | -- |
| 2026-09-09 | Keeley M. Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | Derivative Exercise and Sale | -285 | $144.81 |
| 2026-09-09 | Keeley M. Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | Derivative Exercise and Retained | +305 | -- |
| 2026-08-31 | Daniel Patrick O'Day | Chairperson & CEO | Automatic Disposition | -15,000 | $147.51–149.38 |
| 2026-08-25 | Anthony Welters | Lead Independent Director | Derivative Exercise and Sale | -18,000 | $60.67–148.82 |
| 2026-08-19 | Jeffrey Bluestone | Independent Director | Derivative Exercise and Sale | -5,000 | $61.35–146.36 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 11:00:15 · For reference only, not investment advice and not tailored to your situation.
Gilead Sciences discussion 0 comments